ClinicalTrials.gg

Program

evorpacept

Also written as “Evorpacept (ALX148)” and “Evorpacept”.

Its studies are mostly in Squamous Cell Carcinoma of Head and Neck · Breast Neoplasms · Stomach Neoplasms · Neoplasm Metastasis · Urinary Bladder Neoplasms, led by 2 companies.

Furthest: phase 3, since Jul 27, 20219 company-led studies, 3 open or runningNext primary completion: Dec 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
ALX Oncology83 open or runningphase 3since Jul 27, 2021Dec 15, 2016Dec 2027phase 2 · NCT07007559
Jazz Pharmaceuticals10 open or runningphase 2since Aug 23, 2021Aug 23, 2021none ahead

Also a collaborator on its studies: Eli Lilly and Merck.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 15, 2016First study: phase 1 study in Neoplasm MetastasisNew to ALX OncologyALX Oncology · NCT03013218 · 174 enrolled · United States, South Korea
  2. Jun 2, 2020Phase 1 study in Higher Risk Myelodysplastic SyndromesALX Oncology · NCT04417517 · 65 enrolled · United States, South Korea, Spain
  3. Dec 15, 20202 phase 2 studies in Head and Neck NeoplasmsALX Oncology · NCT04675333, NCT04675294
  4. Feb 11, 2021Phase 1 study in Leukemia, Myeloid, AcuteALX Oncology · NCT04755244 · 14 enrolled · United States
  5. Jul 27, 2021Phase 3 study in Stomach NeoplasmsALX Oncology · NCT05002127 · 127 enrolled · United States, Australia, Belgium and more
  6. Aug 23, 2021Jazz Pharmaceuticals's first study: phase 2 study in HER2-expressing CancersNew to Jazz PharmaceuticalsJazz Pharmaceuticals · NCT05027139 · 52 enrolled · United States
  7. Aug 30, 2022Phase 1 study in Urinary Bladder NeoplasmsALX Oncology · NCT05524545 · 36 enrolled · United States
  8. May 22, 2025Phase 2 study in Breast NeoplasmsALX Oncology · NCT07007559 · 120 planned · United States, Canada, France and more

Ahead

  1. Dec 2027Primary completion: phase 2 study in Breast NeoplasmsALX Oncology · NCT07007559

TargetBeta

CD47 →read by rule
“Leukocyte surface antigen CD47 inhibitor”ChEMBL 37, by rule

Other programs on CD47

ProgramCompanyFurthest phaseStudies
ligufalimabruleAkesophase 311
Anti-PD-1/CD47 Fusion Protein HX009rulehangzhou-hanx-biopharmaceuticals-ltdphase 25
CD47 Antagonist AUR103 CalciumruleDr. Reddy's Laboratoriesphase 22
1200mg of tqb2928 injectionSino Biopharmaceuticalphase 12

Studies

All 9 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07007559Breast Neoplasms · United States, Canada, France and more2RecruitingALX OncologyDec 2027120
NCT05524545Urinary Bladder Neoplasms · United States1CompletedALX OncologyJun 27, 202536
NCT05027139HER2-expressing Cancers · United States2CompletedJazz PharmaceuticalsAug 29, 202552
NCT05002127Stomach Neoplasms · United States, Australia, Belgium and more3CompletedALX OncologyMay 24, 2024127
NCT04755244Leukemia, Myeloid, Acute · United States1TerminatedALX OncologyMay 5, 202314
NCT04675333Head and Neck Neoplasms · United States, Australia, Belgium and more2Active, not recruitingALX OncologyMar 3, 2025172
NCT04675294Head and Neck Neoplasms · United States, Australia, Belgium and more2Active, not recruitingALX OncologyMar 3, 2025189
NCT04417517Higher Risk Myelodysplastic Syndromes · United States, South Korea, Spain1TerminatedALX OncologyJan 17, 202565
NCT03013218Neoplasm Metastasis · United States, South Korea1CompletedALX OncologyFeb 1, 2022174

How it is read

Names in the registry

  • “evorpacept”, 4 entries
  • “Evorpacept (ALX148)”, 3 entries
  • “Evorpacept”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.